Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A.
30 postmenopausal patients with metastatic breast cancer were treated with three different doses of fadrozole hydrochloride (CGS 169 49A), a non-steroidal competitive aromatase inhibitor. The effect of 0.5, 1 and 2 mg given twice daily upon the levels of oestrogens, their androgen precursors and upon the concentration of sex hormone binding globulin (SHBG) was investigated after 1 and 3 months and then every 3 months until progression of disease. A significant reduction in the serum concentration of oestrone (P < 0.0001) was obtained at all doses. Also, the serum concentration of oestrone sulphate was significantly reduced (P < 0.0001). However, after 1 month, the concentration was significantly different from pretreatment levels (P < 0.01) only at the 4 mg daily dose. A decline was also observed in the concentration of SHBG (P < 0.05), with a concomitant elevation of the percentage non-SHBG-bound oestradiol. The androgens, testosterone and dehydroepiandrosterone sulphate, were unaltered during treatment, while androstendione was significantly elevated at the 2 mg daily dose (P < 0.001).
Svenstrup
B
B
Department of Clinical Biochemistry, Statens Seruminstitut, Copenhagen, Denmark.
Herrstedt
J
J
Brünner
N
N
Bennett
P
P
Wachmann
H
H
Dombernowsky
P
P
D000368:Aged; D000728:Androgens / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000097:blood*; D017316:Fadrozole / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017698:Postmenopause / Q000097:blood; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism*; D013997:Time Factors
D000728:Androgens; D004967:Estrogens; D012738:Sex Hormone-Binding Globulin; D017316:Fadrozole